News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alvotech
< Previous
1
2
3
Next >
Alvotech Announces Closing of Private Debt Financing
July 11, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
July 02, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Issues New Shares to Holders of Convertible Bonds
July 01, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
July 01, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
June 26, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
June 18, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and STADA add to strategic alliance through denosumab partnership
June 11, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Strategic Refinancing Agreement
June 07, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
May 29, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
May 21, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
May 21, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
RDY
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
May 20, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
TEVA
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
May 13, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
May 02, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
TEVA
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
April 24, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
April 16, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
TEVA
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
April 03, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Increase in Number of Own Shares
March 22, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
March 20, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
March 05, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Appoints Interim Chief Quality Officer
February 29, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
February 26, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
TEVA
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
February 15, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
January 29, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
January 19, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
January 10, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
January 03, 2024
From
Alvotech
Via
GlobeNewswire
Tickers
ALVO
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.